During starvation, fasting, or a diet containing little digestible carbohydrates, the circulating
insulin levels are decreased. This promotes lipolysis, and the breakdown of fat becomes the …

Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its
increasing global prevalence and because chronic hyperglycemic states are closely linked …

Abstract Purpose of Review This review offers a critical narrative evaluation of emerging
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Background In most patients with type 1 diabetes, adequate glycemic control is not achieved
with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral …

Diabetic ketoacidosis (DKA), hyperglycaemic hyperosmolar state (HHS) and hypoglycaemia
are serious complications of diabetes mellitus that require prompt recognition, diagnosis and …

Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications
shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood …

Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are the most
serious and life-threatening hyperglycemic emergencies in patients with diabetes. Although …

Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …